Adalimumab in ulcerative colitis: Ready for prime time
- 1 January 2013
- journal article
- review article
- Published by Elsevier BV in Digestive and Liver Disease
- Vol. 45 (1), 8-13
- https://doi.org/10.1016/j.dld.2012.05.021
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- 52-Week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressantsGut, 2011
- What’s hot in inflammatory bowel disease in 2011?World Journal of Gastroenterology, 2011
- Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabAlimentary Pharmacology & Therapeutics, 2010
- Health related quality of life in inflammatory bowel disease: The impact of surgical therapyWorld Journal of Gastroenterology, 2010
- Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the Clinical SettingJournal of Gastroenterology and Hepatology, 2009
- Adalimumab in ulcerative colitis: Two cases of mucosal healing and clinical response at two yearsWorld Journal of Gastroenterology, 2009
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Infliximab for acute, not steroid-refractory ulcerative colitisEuropean Journal of Gastroenterology & Hepatology, 2004
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2004